Autologous Platelet-Released Growth Factor and Sexual Dysfunction Amendment: A Pilot Clinical Trial of Successful Improvement Sexual Dysfunction after Pelvic Irradiation

Document Type : Research Articles


1 Department of Gynecology and Obstetrics, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

2 Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

3 Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Department of Pathology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


Sexual dysfunction (SDF) is a common sequel to cancer treatment which affects the quality of life in women
treated with pelvic radiotherapy. The aim of this study was to evaluate the safety, symptom resolution and objective
improvement the injection of autologous platelet released growth factor (APRGF) for treatment of SDF in cited patients.
This prospective pilot study enrolled 10 cancer-free patients with SDF who underwent pelvic radiotherapy at least 5
years ago, randomly. Each patient was received 1-2 cc APRGF within four weeks and all patients were re-evaluated
at eight weeks and six months. CD34 immuno histochemistry and Masson’s trichrome staining were performed on
vaginal biopsy section for angiogenesis and fibrosis assay respectively. Sexual satisfaction after the injection of APRFG
was clinically difference and the entire patient had sexual satisfaction. In the patient’s follow-up, none of them needs
to repeat the treatment. Our results declared that APRGF injection was effective and symptoms were disappeared in
the entire patients. Significant objective improvements in vaginal diameter (mean before injection, 6.5 cm vs 7.1 cm
after injection) (p-value = 0.001) and vaginal flexibility (mean before treatment, 0.72 cm vs 1.85 cm after injection)
(P-value = 0.026) were observed. Characteristics of discharge before the injection in 60% of patients were included
dry vagina and 40% had mild discharge but after injection 40% of patients had moderate and also 60% had mild and
sufficient discharge (P-value= 0.190). Overally, our patients reported better sexual function and showed better vaginal
function indexes, after APRFG injection.


Main Subjects